18 results with keyword: 'gemtuzumab ozogamicin mylotarg treatment myeloid leukemia ongoing trials'
26 Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila
N/A
& Mylotarg Study Group (2003) Gemtuzumab ozogamicin in combination with induction chemo- therapy for the treatment of patients with de novo acute myeloid leukemia: two
N/A
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: fi nal results of AML-15B, a phase 2 study of
N/A
Keywords: acute myeloid leukemia; patients with organ dysfunction; gemtuzumab ozogamicin.. 26
N/A
Gemtuzumab Ozogamicin (Mylotarg [Registered]) Expanded Access Protocol for Treatment of Patients in the United States with Relapsed/ Refractory Acute Myelogenous Leukemia Who
N/A
(2009) Prelimi- nary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial com- paring the addition of gemtuzumab ozogamicin to stan-
N/A
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the
N/A
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of
N/A
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by
N/A
We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction)
N/A
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Burnett AK, Russell NH, Hills RK,
N/A
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Efficacy of
N/A
Li X, Xu SN, Qin DB, Tan Y, Gong Q, Chen JP (2014) Effect of adding gemtuzumab ozogamicin to induction chemotherapy for new- ly diagnosed acute myeloid leukemia: a meta-analysis
N/A
Refer to PIX/ASA 7.x and above: Mail Server Access on Inside Network Configuration Example for instructions on how to set up the PIX/ASA Security Appliance for access to a
N/A
Gemtuzumab ozogamicin-based salvage, followed by allogeneic hematopoi- etic stem cell transplantation, is highly effective in young patients with core binding factor (CBF) acute
N/A
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Renneville A, Abdelali
N/A
Gupta3 introduced a different Durrmeyer type modification of the Bernstein polynomials and estimated the rate of convergence for functions of bounded variation.. The
N/A